Pharmafile Logo
Pharmafocus logo
Advanced Search

datopotamab deruxtecan

Showing 3 posts of 3 posts found.

AstraZeneca shares results from phase 3 TROPION-Lung01 trial

May 28, 2024
Medical Communications AstraZeneca, Daiichi Sankyo, NSCLC, Oncology, clinical trial, datopotamab deruxtecan

AstraZeneca has announced results from the phase 3 TROPION-Lung01 trial of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (Dato-DXd). The survival …

News
louis-reed-pwckf7l4-no-unsplash_5

EMA validates two applications for datopotamab deruxtecan for cancer treatments

March 4, 2024
Medical Communications CHMP, Daiichi Sankyo, EMA, Oncology, datopotamab deruxtecan

AstraZeneca has announced that the European Medicines Agency (EMA) has validated to marketing authorisation applications (MAAs) for AstraZeneca and Daiichi …

News
lungs

AstraZeneca shares results from phase 3 trial of datopotamab deruxtecan for NSCLC

July 3, 2023
Medical Communications AstraZeneca, NSCLC, Oncology, clinical trial, datopotamab deruxtecan

AstraZeneca has announced results from its TROPION-Lung01 phase 3 trial for its TROP2-directed antibody drug conjugate, developed in collaboration with …

News
The Gateway to Local Adoption Series

Latest content

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026

Alvotech appoints Lisa Graver as CEO

February 3, 2026

HonorHealth Research Institute announces first patient dosed with new stroke treatment

February 2, 2026

Accord Healthcare appoints Paul Burden as Associate Vice President and Country Head UK

February 2, 2026

Historic UN declaration supporting mental health – treatment to be given similar priority to chronic diseases

January 30, 2026